Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Change in Cash (2020 - 2025)

Mirum Pharmaceuticals has reported Change in Cash over the past 6 years, most recently at $15.7 million for Q4 2025.

  • Quarterly results put Change in Cash at $15.7 million for Q4 2025, up 3461.37% from a year ago — trailing twelve months through Dec 2025 was $75.2 million (up 218.67% YoY), and the annual figure for FY2025 was $75.2 million, up 218.67%.
  • Change in Cash for Q4 2025 was $15.7 million at Mirum Pharmaceuticals, down from $53.9 million in the prior quarter.
  • Over the last five years, Change in Cash for MIRM hit a ceiling of $147.8 million in Q2 2023 and a floor of -$69.3 million in Q2 2024.
  • Median Change in Cash over the past 5 years was $3.5 million (2021), compared with a mean of $7.8 million.
  • Biggest five-year swings in Change in Cash: plummeted 273.23% in 2024 and later soared 3461.37% in 2025.
  • Mirum Pharmaceuticals' Change in Cash stood at $75.5 million in 2021, then tumbled by 110.27% to -$7.8 million in 2022, then crashed by 115.74% to -$16.7 million in 2023, then soared by 97.22% to -$466000.0 in 2024, then soared by 3461.37% to $15.7 million in 2025.
  • The last three reported values for Change in Cash were $15.7 million (Q4 2025), $53.9 million (Q3 2025), and $16.4 million (Q2 2025) per Business Quant data.